Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

NCT01868451 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

118

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

DRUG: Brentuximab vedotin (SGN-35)
DRUG: Doxorubicin HCL
DRUG: Vinblastine Sulfate
DRUG: Dacarbazine
RADIATION: Involved-Site Radiation Therapy (ISRT)
PROCEDURE: Interim PET
RADIATION: consolidation volume RT (CVRT)

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]